[HTML][HTML] In vitro biodistribution studies on clinically approved FGFR inhibitors ponatinib, nintedanib, erlotinib and the investigational inhibitor KP2692
O Dömötör, M Mathuber, CR Kowol - European Journal of Pharmaceutical …, 2024 - Elsevier
Binding towards human serum albumin (HSA) and α1-acid glycoprotein (AGP) of three
approved fibroblast growth factor receptor (FGFR) inhibitors ponatinib (PON), nintedanib …
approved fibroblast growth factor receptor (FGFR) inhibitors ponatinib (PON), nintedanib …
Comparative studies on the human serum albumin binding of the clinically approved EGFR inhibitors gefitinib, erlotinib, afatinib, osimertinib and the investigational …
Binding interactions between human serum albumin (HSA) and four approved epidermal
growth factor receptor (EGFR) inhibitors gefitinib (GEF), erlotinib (ERL), afatinib (AFA) …
growth factor receptor (EGFR) inhibitors gefitinib (GEF), erlotinib (ERL), afatinib (AFA) …
Abstract C071: pharmacokinetics and pharmacodynamics of pemigatinib, a potent and selective inhibitor of FGFR 1, 2, and 3, in patients with advanced malignancies
T Ji, C Lihou, E Asatiani, L Féliz, H Overholt… - Molecular Cancer …, 2019 - AACR
Pemigatinib is a potent inhibitor of fibroblast growth factor receptors (FGFR) 1, 2, and 3 with
selectivity against other kinases and is currently being studied in solid tumors expressing …
selectivity against other kinases and is currently being studied in solid tumors expressing …
Abstract CT228: Formulation switch and pharmacokinetics/pharmacodynamics of Debio 1347 (CH5183284), a novel FGFR inhibitor, in a first-in-human dose …
V Nicolas-Metral, A Vaslin, JG Supko, K Nakai, N Ishii… - Cancer Research, 2015 - AACR
Background: Deregulated fibroblast growth factor receptor (FGFR) signaling is associated
with tumorigenesis. The oral selective FGFR 1, 2, 3 inhibitor Debio 1347, a …
with tumorigenesis. The oral selective FGFR 1, 2, 3 inhibitor Debio 1347, a …
Preliminary clinical pharmacokinetics and pharmacodynamics of Debio 1347 (CH5183284), a novel FGFR inhibitor.
C Zanna, A Vaslin, MH Voss, RS Heist, C Hierro… - 2015 - ascopubs.org
2540 Background: Deregulated fibroblast growth factor receptor (FGFR) signaling is
associated with tumorigenesis. Debio 1347 is an orally-available ATP competitive inhibitor …
associated with tumorigenesis. Debio 1347 is an orally-available ATP competitive inhibitor …
LC‐ESI‐MS/MS method validation for simultaneous quantification of FDA‐approved anticancer agents futibatinib and binimetinib in rat plasma: Insights from …
SD Dadge, S Yadav, S Rathaur… - Biomedical … - Wiley Online Library
This study investigates the combination of FGFR inhibitor futibatinib (FTB) and MEK inhibitor
binimetinib (BTB) for KRASmt NSCLC therapy. An analytical method was developed and …
binimetinib (BTB) for KRASmt NSCLC therapy. An analytical method was developed and …
Population pharmacokinetics analysis of pemigatinib in patients with advanced malignancies
T Ji, X Chen, X Liu… - Clinical Pharmacology in …, 2022 - Wiley Online Library
Pemigatinib is a fibroblast growth factor receptor 1–3 inhibitor used to treat
cholangiocarcinoma. A compartmental population pharmacokinetics model was developed …
cholangiocarcinoma. A compartmental population pharmacokinetics model was developed …
[HTML][HTML] Optimization and validation of stability indicating RP-HPLC method for the quantification of gefitinib in bulk drug and nanoformulations: An application towards …
Gefitinib (GFB) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used
primarily to treat non-small cell lung cancer (NSCLC), but it also works by lowering AKT and …
primarily to treat non-small cell lung cancer (NSCLC), but it also works by lowering AKT and …
Effect of a high-fat meal on the relative bioavailability of H3B-6527, a novel FGFR4 inhibitor, in healthy volunteers
N Rioux, A Kim, D Nix, T Bowser, M Warmuth… - Cancer Chemotherapy …, 2019 - Springer
Abstract Purpose This Phase I study estimated the effect of a high-fat meal on the
pharmacokinetics (PK) of H3B-6527, a covalent inhibitor of the fibroblast growth factor …
pharmacokinetics (PK) of H3B-6527, a covalent inhibitor of the fibroblast growth factor …
Discovery and pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor
TPS Perera, E Jovcheva, L Mevellec, J Vialard… - Molecular cancer …, 2017 - AACR
Fibroblast growth factor (FGF) signaling plays critical roles in key biological processes
ranging from embryogenesis to wound healing and has strong links to several hallmarks of …
ranging from embryogenesis to wound healing and has strong links to several hallmarks of …